Sysmex (6869) AI Stock Analysis

• Market Cap: $1.06T
• Dividend Yield: 1.74%
• Average Volume (3M): 2.38M
• Price to Earnings (P/E): 22.5
• Beta (1Y): 0.64
• Revenue Growth: 1.51%
• EPS Growth: -12.59%
• Country: JP
• Employees: 10,042
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 629,480,100
• 10 Day Avg. Volume: 2,693,210
• 30 Day Avg. Volume: 2,377,620
• PEG Ratio: 3.84
• Price to Book (P/B): 3.81
• Price to Sales (P/S): 3.48
• P/FCF Ratio: 29.97
• Enterprise Value/Market Cap: 1.46
• Enterprise Value/Revenue: 3.10
• Enterprise Value/Gross Profit: 5.85
• Enterprise Value/Ebitda: 13.52
• 1Y Price Target: $2,320.56
• Price Target Upside: 48.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: ¥1,668.00 ▲(7.03% Upside)

Sysmex's overall stock score reflects a combination of strong financial health and operational efficiency, counterbalanced by bearish technical indicators and a high valuation. The company's robust balance sheet and profitability are significant strengths, but the current market momentum and valuation metrics suggest caution. The absence of positive corporate events or earnings call highlights further tempers the outlook.

Sysmex Business Overview & Revenue Model

Company Description

Sysmex Corporation (6869) is a global leader in the field of in vitro diagnostics (IVD) and laboratory automation. Headquartered in Kobe, Japan, the company specializes in developing and manufacturing diagnostic instruments, reagents, and software for clinical laboratories. Sysmex operates primarily in the hematology, coagulation, immunochemistry, and urinalysis sectors, offering a comprehensive range of products that support healthcare professionals in disease diagnosis and management.

How the Company Makes Money

Sysmex generates revenue through several key streams, primarily from the sale of diagnostic instruments and related reagents. The company offers a wide array of hematology analyzers and coagulation testing systems, which are essential for laboratories and healthcare facilities. Additionally, Sysmex earns revenue from consumables, such as reagents and control materials, used in conjunction with its diagnostic equipment. Service contracts and maintenance agreements for these instruments also contribute significantly to its revenue. The company has established strategic partnerships with various healthcare providers and research institutions, which enhance its market presence and facilitate the development of innovative diagnostic solutions. Furthermore, Sysmex's focus on expanding its presence in emerging markets and investing in research and development helps drive growth and profitability.

Sysmex Financial Statement Overview

Summary

Sysmex demonstrates strong financial health with efficient operations and a solid balance sheet. While there are concerns about declining revenue growth and free cash flow, the company maintains robust profitability and leverage metrics. Continued focus on revenue growth and cash flow management will be crucial for sustaining long-term financial stability.

Income Statement

Sysmex's income statement shows a strong gross profit margin of over 50% consistently, indicating efficient cost management. However, the TTM data reveals a slight decline in revenue and net profit margins compared to the previous year, signaling potential challenges in maintaining growth. Despite this, the company has maintained healthy EBIT and EBITDA margins, reflecting robust operational efficiency.

Balance Sheet

The balance sheet is solid with a low debt-to-equity ratio, suggesting prudent financial leverage. Return on equity remains strong, indicating effective use of shareholder funds. The equity ratio is stable, highlighting a strong capital structure. However, the increase in total debt over the years warrants monitoring.

Cash Flow

Sysmex's cash flow statement shows a decline in free cash flow growth, which could impact future investments and dividend payouts. The operating cash flow to net income ratio is healthy, indicating good cash generation relative to earnings. However, the decreasing free cash flow to net income ratio suggests potential challenges in converting profits into free cash flow.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	502.43B	508.64B	461.51B	410.50B	363.78B	305.07B
Gross Profit	266.40B	271.98B	242.50B	216.08B	190.59B	154.30B
EBITDA	115.25B	123.85B	115.67B	104.95B	96.12B	75.53B
Net Income	47.19B	53.67B	49.64B	45.78B	44.09B	31.90B
Balance Sheet
Total Assets	639.93B	665.27B	618.92B	531.07B	483.71B	427.48B
Cash, Cash Equivalents and Short-Term Investments	74.48B	89.57B	76.61B	70.33B	75.25B	67.57B
Total Debt	64.48B	64.73B	55.34B	22.59B	22.28B	21.96B
Total Liabilities	177.91B	200.73B	186.02B	142.72B	134.65B	118.81B
Stockholders Equity	461.34B	463.78B	432.05B	387.67B	348.30B	305.32B
Cash Flow
Free Cash Flow	49.60B	59.02B	13.71B	26.33B	26.70B	33.02B
Operating Cash Flow	79.77B	88.25B	63.91B	68.83B	58.74B	58.81B
Investing Cash Flow	-53.46B	-52.49B	-54.97B	-51.75B	-35.05B	-31.13B
Financing Cash Flow	-28.61B	-24.32B	-9.01B	-24.23B	-20.54B	-20.25B

Sysmex Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1558.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6869, the sentiment is Negative. The current price of 1558.5 is below the 20-day moving average (MA) of 1645.23, below the 50-day MA of 1762.89, and below the 200-day MA of 2305.43, indicating a bearish trend. The MACD of -78.07 indicates Positive momentum. The RSI at 34.53 is Neutral, neither overbought nor oversold. The STOCH value of 11.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6869.

Sysmex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4543	73 Outperform	¥3.63T	27.78	9.31%	1.18%	7.68%	10.08%
7733	72 Outperform	$2.13T	19.23	13.13%	1.07%	0.42%	34.76%
7747	68 Neutral	$667.11B	52.35	10.09%	0.84%	13.53%	-7.39%
7741	68 Neutral	$8.61T	41.34	20.74%	1.04%	8.83%	8.63%
8086	62 Neutral	¥242.85B	22.30	4.38%	2.03%	6.04%	733.13%
6869	60 Neutral	$1.06T	22.55	9.80%	1.74%	1.51%	-12.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sysmex Corporate Events

Sysmex Corporation Reports Decline in Semi-Annual Earnings

Sysmex Corporation is a Japanese company specializing in the development and sale of diagnostic instruments and reagents, primarily serving the healthcare sector with a focus on hematology and immunochemistry.

Sysmex Revises Financial Forecast Amid Weak Sales in Key Markets

Sysmex Corporation reported that its actual financial results for the six months ending September 30, 2025, were below the forecasted figures due to weaker sales in China and Japan. Consequently, the company has revised its full-year financial forecast for the fiscal year ending March 31, 2026, anticipating declines in net sales, operating profit, and profit attributable to owners. The company is adjusting its foreign exchange assumptions and aims to improve profitability by controlling expenses, although challenges in key markets persist.

The most recent analyst rating on (JP:6869) stock is a Hold with a Yen2000.00 price target. To see the full list of analyst forecasts on Sysmex stock, see the JP:6869 Stock Forecast page.

Sysmex Reports Decline in Semi-Annual Financial Performance

Sysmex Corporation reported a decline in its financial performance for the first six months of the fiscal year ending March 31, 2026, with net sales decreasing by 4.1% and operating profit dropping by 25.9% compared to the previous year. Despite the downturn, the company announced a commemorative dividend in celebration of its 30th anniversary of listing, reflecting its commitment to shareholder returns. The financial forecast for the year ending March 31, 2026, anticipates modest growth in net sales but a decrease in operating profit, highlighting challenges in maintaining profitability amidst market conditions.

The most recent analyst rating on (JP:6869) stock is a Hold with a Yen2000.00 price target. To see the full list of analyst forecasts on Sysmex stock, see the JP:6869 Stock Forecast page.